BioSpace News Archive

Oculis Holding AG (Nasdaq: OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced First Patient First Visit (FPFV) in OCS-01 Phase 3 OPTIMIZE-2 trial for the treatment of inflammation and pain following cataract surgery.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 10:30 a.m. PT/1:30 p.m. ET.

Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB® for the removal of tumor cells from surgical shed blood, today announced that the last patient in its certification study REMOVE has successfully completed the trial. Top line results are expected in Q1 2024.

Addex Therapeutics announced that its shareholders approved, with a large majority, all of the proposals of the board of directors at its Extraordinary General Meeting held on December 19, 2023.

Poolbeg Pharma announces the positive outputs from the lab-based analysis and successful prioritisation of the Respiratory Syncytial Virus drug targets and treatments identified as part of its artificial intelligence led programme.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia announced today the submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for AUR200, a potential next generation therapy for B-cell mediated autoimmune diseases.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, is scheduled to participate in a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on Thursday, Jan. 4, 2024, at 12:45 p.m. EST.

Rentschler Biopharma SE announced that the company has secured a major client for the new Rentschler Biopharma Manufacturing Center facility at its manufacturing site in Milford, Massachusetts.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all 120 patients in its Phase II trial of Allocetra™ in patients with sepsis.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the launch of the Myriad Collaborative Research Registry™.